Journal
KIDNEY INTERNATIONAL
Volume 76, Issue 11, Pages 1137-1141Publisher
ELSEVIER SCIENCE INC
DOI: 10.1038/ki.2009.357
Keywords
end-stage renal disease; EPO resistance; hepcidin; matriptase-2; TMPRSS6
Categories
Funding
- Ralph Wilson Medical Research Foundation
- Bakken Heart-Brain Institute
- National Institutes of Health [R01 HL089298]
Ask authors/readers for more resources
Iron deficiency anemia is a common complication in end-stage renal disease (ESRD) and impairs the therapeutic efficacy of recombinant erythropoietin. Oral or parental iron supplements usually are effective in treating iron deficiency anemia. Some patients, however, respond poorly to iron supplements and are diagnosed as having iron-refractory iron deficiency anemia. The condition exacerbates ESRD but its underlying mechanism was unclear. Hepcidin is a central player in iron homeostasis. It downregulates the iron exporter ferroportin, thereby inhibiting iron absorption, release and recycling. In ESRD, plasma hepcidin levels are elevated, which contributes to iron deficiency in patients. Matriptase-2, a liver transmembrane serine protease, has been found to have a major role in controlling hepcidin gene expression. In mice, defects in the Tmprss6 gene encoding matriptase-2 result in high hepcidin expression and cause severe microcytic anemia. Similarly, mutations in the human TMPRSS6 gene have been identified in patients with iron-refractory iron deficiency. Thus, matriptase-2 is critical for iron homeostasis and may have an important role in ESRD. Kidney International (2009) 76, 1137-1141; doi:10.1038/ki.2009.357; published online 23 September 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available